Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Breast Cancer

  Free Subscription


Articles published in Oncol Rep

Retrieve available abstracts of 24 articles:
HTML format



Single Articles


    January 2023
  1. BONTEMPS I, Lallemand C, Biard D, Dechamps N, et al
    Loss of CD24 promotes radiation and chemoresistance by inducing stemness properties associated with a hybrid E/M state in breast cancer cells.
    Oncol Rep. 2023;49.
    PubMed     Abstract available


    November 2022
  2. ARMANDO R, Cabrera M, Vilarullo R, Chinestrad P, et al
    In vitro characterization and rational analog design of a novel inhibitor of telomerase assembly in MDA MB 231 breast cancer cell line.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


  3. JIANG H, Li X, Wang W, Hu Y, et al
    MYCL promotes the progression of triplenegative breast cancer by activating the JAK/STAT3 pathway.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


    October 2022
  4. HU H, Xiang Y, Zhang XY, Deng Y, et al
    CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


    September 2022
  5. ZHUANG Y, Li X, Zhan P, Pi G, et al
    HIF1alpha and MBP1 are associated with the progression of breast cancer cells by repressing betacatenin transcription.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


    July 2022
  6. SUI Y, Zhang X, Yang H, Wei W, et al
    [Retracted] MicroRNA133a acts as a tumour suppressor in breast cancer through targeting LASP1.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


  7. JIRAPONGWATTANA N, Thongchot S, Chiraphapphaiboon W, Chieochansin T, et al
    Mesothelinspecific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3treated selfdifferentiated dendritic cells.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


  8. HAM A, Cho MH, Won HS, Jo J, et al
    betacatenin blockers enhance the effect of CDK4/6 inhibitors on stemness and proliferation suppression in endocrineresistant breast cancer cells.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


    June 2022
  9. JIANG Q, He M, Ma MT, Wu HZ, et al
    [Corrigendum] MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


  10. LI J, Liu L, Chen Y, Wu M, et al
    Ribosome assembly factor PNO1 is associated with progression and promotes tumorigenesis in triplenegative breast cancer.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


  11. TAKEDA T, Tsubaki M, Matsuda T, Kimura A, et al
    EGFR inhibition reverses epithelialmesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    May 2022
  12. TSAO AN, Chuang YS, Lin YC, Su Y, et al
    Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    March 2022
  13. ZHANG H, Wei N, Zhang W, Shen L, et al
    [Retracted] lncRNA SNHG3 promotes breast cancer progression by acting as a miR326 sponge.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


  14. CHEN Y, Wei L, Zhang X, Liu X, et al
    [Corrigendum] 3Bromopyruvate sensitizes human breast cancer cells to TRAILinduced apoptosis via the phosphorylated AMPKmediated upregulation of DR5.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    February 2022
  15. CAO W, Shen R, Richard S, Liu Y, et al
    Inhibition of triplenegative breast cancer proliferation and motility by reactivating p53 and inhibiting overactivated Akt.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    January 2022
  16. INAISHI T, Shibata M, Ichikawa T, Kanda M, et al
    Platelet isoform of phosphofructokinase accelerates malignant features in breast cancer.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


  17. TORNROOS R, Tina E, Gothlin Eremo A
    SLC7A5 is linked to increased expression of genes related to proliferation and hypoxia in estrogenreceptorpositive breast cancer.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    December 2021
  18. KIM JM, Park J, Noh EM, Song HK, et al
    Downregulation of matriptase suppresses the PAR2/PLCgamma2/PKCmediated invasion and migration abilities of MCF7 breast cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  19. THONGCHOT S, Jamjuntra P, Prasopsiri J, Thuwajit P, et al
    Establishment and characterization of novel highly aggressive HER2positive and triplenegative breast cancer cell lines.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    November 2021
  20. JEON SM, Lim JS, Park SH, Lee JH, et al
    Wnt signaling promotes tumor development in part through phosphofructokinase 1 platelet isoform upregulation.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    July 2021
  21. CHIU YJ, Tsai FJ, Bau DT, Chang LC, et al
    Nextgeneration sequencing analysis reveals that MTH3, a novel curcuminoid derivative, suppresses the invasion of MDAMB231 triplenegative breast adenocarcinoma cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    May 2021
  22. TREMANTE E, Sibilio L, Centola F, Knutti N, et al
    TOOLBOX: StrepTagged nanoassemblies of antibodydrugconjugates (ADC) for modular and conditional cancer drugging
    Oncol Rep. 2021;45.
    PubMed     Abstract available


    April 2021
  23. CALAF GM, Bleak TC, Roy D
    Signs of carcinogenicity induced by parathion, malathion, and estrogen in human breast epithelial cells (Review).
    Oncol Rep. 2021;45.
    PubMed     Abstract available


    February 2021
  24. LU N, Zhang M, Lu L, Liu YZ, et al
    miRNA4903p promotes the metastatic progression of invasive ductal carcinoma.
    Oncol Rep. 2021;45:706-716.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: